Michael Caligiuri, MD
Development and normal role of the body's large granular lymphocytes called natural killer cells, and to exploit their properties in order to develop effective therapies against cancer and immune deficiency.

Lei Cao, PhD
Use multidisciplinary approaches to further define a novel brain-fat axis (hypothalamic-sympathoneural-adipocyte axis), identify molecular mediators, and develop both genetic and pharmacological approaches to combat obesity, metabolic syndromes, and cancer.

Arnab Chakravarti, MD
Signal Transduction Pathways in Glioblastomas and prostate cancer.

Timothy Cripe, MD, PhD
Developing and studying targeted therapeutics for non-CNS solid tumors in children, particularly sarcomas and neuroblastoma.

Deliang Guo, PhD
Understanding the molecular mechanisms of metabolic reprogramming in cancer cells, and unraveling the molecular link between oncogenic signaling and cancer metabolism.

Edwin Horwitz, MD, PhD
Developing novel therapeutic strategies to improve outcomes after BMT and using mesenchymal stem/stromal cells as cell therapy for a broad array of malignant and nonmalignant disorders.

Jaime Imitola, MD
Identify and validate genes that mediate the responses of neural stem cells (NSCs) to CNS injury in multiple sclerosis and brain cancer in the so-called injury-induced stem cell niches.

Balveen Kaur, PhD
Investigate changes in the tumor microenvironment associated with disease progression and in response to treatment to design better therapies.

Russell Lonser, MD
Development of direct nervous system drug delivery paradigms for targeted therapy, as well as investigation of tumor pathogenesis and biology in familial neoplasia syndromes.

Vinay Puduvalli, MD
Understanding the role of epigenetics in brain tumor biology and treatment resistance and translating these findings into new treatment options; identifying means to accelerate tumor cell death by activating death pathways in brain tumors.

Leah Pyter, PhD
Peripheral tumor growth triggers inflammation in the brain and is associated with depressive-like behavior and cognitive impairments.

Monica Venere, PhD
Elucidate points of fragility for glioblastoma using cell and molecular biology as well as animal models and exploit these findings to develop new treatment modalities and/or improve on current standard of care therapies.